OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study
S Keshav, J Goh, A Hart, S Levison, S McLaughlin, Avan Aa der, R Galien, Y Pan, L Meuleners, C Jamoul, C Tasset, P Harrison, S Vermeire
Gut Jul 2017, 66 (Suppl 2) A25; DOI: 10.1136/gutjnl-2017-314472.48
